Strategic priorities for respiratory syncytial virus (RSV) vaccine development
- PMID: 23598484
- PMCID: PMC3919153
- DOI: 10.1016/j.vaccine.2012.11.106
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
Abstract
Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naïve young infant, the RSV naïve child ≥ 6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naïve child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naïve child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naïve children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines. We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.J Virol. 2017 May 12;91(11):e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1. J Virol. 2017. PMID: 28298602 Free PMC article.
-
The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.Allergy Asthma Proc. 2023 Jul 26;44(4):220-228. doi: 10.2500/aap.2023.44.230030. Allergy Asthma Proc. 2023. PMID: 37236777 Review.
-
A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.J Virol. 2020 Dec 22;95(2):e01512-20. doi: 10.1128/JVI.01512-20. Print 2020 Dec 22. J Virol. 2020. PMID: 33115876 Free PMC article.
-
Respiratory syncytial virus vaccine development.Semin Immunol. 2013 Apr;25(2):160-71. doi: 10.1016/j.smim.2013.04.011. Epub 2013 Jun 15. Semin Immunol. 2013. PMID: 23778071 Review.
-
Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.Am J Respir Crit Care Med. 2021 Mar 1;203(5):594-603. doi: 10.1164/rccm.202005-1660OC. Am J Respir Crit Care Med. 2021. PMID: 32871092 Free PMC article.
Cited by
-
Respiratory Syncytial Virus Infection in Older Adults: An Update.Drugs Aging. 2024 Jun;41(6):487-505. doi: 10.1007/s40266-024-01118-9. Epub 2024 May 7. Drugs Aging. 2024. PMID: 38713299 Free PMC article. Review.
-
Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.Nat Commun. 2024 Mar 14;15(1):2202. doi: 10.1038/s41467-024-46295-8. Nat Commun. 2024. PMID: 38485927 Free PMC article.
-
Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.Pathogens. 2023 Oct 19;12(10):1259. doi: 10.3390/pathogens12101259. Pathogens. 2023. PMID: 37887775 Free PMC article. Review.
-
Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models.NPJ Vaccines. 2023 Sep 29;8(1):143. doi: 10.1038/s41541-023-00729-4. NPJ Vaccines. 2023. PMID: 37773185 Free PMC article.
-
Genomic similarity and antibody-dependent enhancement of immune serum potentially affect the protective efficacy of commercial MLV vaccines against NADC30-like PRRSV.Virol Sin. 2023 Oct;38(5):813-826. doi: 10.1016/j.virs.2023.08.010. Epub 2023 Sep 1. Virol Sin. 2023. PMID: 37660949 Free PMC article.
References
-
- Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among U.S. children, 1980–1995. JAMA. 1999;282:1440–1447. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical